Jupiter Neurosciences (JUNS) Stock: Buy, Sell, or Hold?
JUNS - Jupiter Neurosciences, Inc. Common Stock
$2.55
0.05 (2.00%)
▲
5d:
-4.49%
30d:
-25.66%
90d:
+1052.8%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When JUNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: JUNS trades at premium valuation expecting 29.4% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: JUNS trades at premium valuation expecting 29.4% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: JUNS is currently trading at $2.55, which is considered slightly low relative to its 30-day fair value range of $2.52 to $3.96. From a valuation perspective, the stock is trading at a premium (Forward PE: 42.5) compared to its historical average (19.6). At these levels, the market is pricing in 29.4% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, JUNS is in a strong uptrend. Immediate support is located at $2.35, while resistance sits at $3.68.
Market Sentiment: JUNS scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $30.00 (+1076.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, JUNS is in a strong uptrend. Immediate support is located at $2.35, while resistance sits at $3.68.
Market Sentiment: JUNS scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $30.00 (+1076.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.52 -
$3.96
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
85.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1076.5% below Wall St target ($30.00)
- BEARISH: Market expects 29.4% growth - appears too optimistic based on history
- CAUTION: Bottoming setup, but lagging the sector by 36% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$2.52 -
$3.96
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.35
Resistance Level
$3.68
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
42.50
Wall Street Target
$30.00
(+1076.5%)
Valuation Premium vs History
+29.4% premium
PE vs Historical
42.5 vs 19.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+29.4%
(market-implied from PE analysis)
1-Year Target
$3.30
(+29%)
2-Year Target
$4.27
(+67%)
3-Year Target
$5.53
(+117%)
3-Yr Target (if PE normalizes)
(PE: 43→20)
PE COMPRESSION
$2.55
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 03, 2026 7:02 PM ET
Data refreshes hourly during market hours. Next update: 8:02 PM
Data refreshes hourly during market hours. Next update: 8:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JUNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 71 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 66 BUY |
